

## Reviews in IN VIVO 2005-2006-2007-2008

<sup>18</sup>F-FDG PET in the Diagnosis and Follow-up of Thyroid Malignancy. A. AL-NAHHAS, S. KHAN, A. GOGBASHIAN, E. BANTI, L. RAMPIN, D. RUBELLO (*London, UK; Rovigo, Italy*). In Vivo 22: 109-114, 2008.

Estrogen and Progesterone Treatment Mimicking Pregnancy for Protection from Breast Cancer. A. TSUBURA, N. UEHARA, Y. MATSUOKA, K. YOSHIZAWA, T. YURI (*Osaka, Japan*). In Vivo 22: 191-202, 2008.

Control of Interstitial Pneumonia by Drip Infusion of Megadose Vitamin C, Dehydroepiandrosterone and Cortisol. A Short Review of our Experience. M. KODAMA, A. OYAMA, H. TAKAGI (*Nagoya, Japan*). In Vivo 22: 263-268, 2008.

The Role of the Insulin-like Growth Factor 1 (IGF-1) in Skeletal Muscle Physiology. A. PHILIPPOU, M. MARIDAKI, A. HALAPAS, M. KOUTSILIERIS (*Athens, Greece*). In Vivo 21: 45-55, 2007.

Antioxidant Gene Therapeutic Approaches to Normal Tissue Radioprotection and Tumor Radiosensitization. J.S. GREENBERGER, M. W. EPPERLY (*Pittsburgh, PA, USA*). In Vivo 21: 141-146, 2007.

TNF/VEGF Cross-talk in Chronic Inflammation-related Cancer Initiation and Progression: An Early Target in Anticancer Therapeutic Strategy. F. GUADAGNI, P. FERRONI, R. PALMIROTTA, I. PORTARENA, V. FORMICA, M. ROSELLI (*Rome, Italy*). In Vivo 21: 147-162, 2007.

Photooxygenation, Photodegradation and Antioxidative Activity of Platonin, a Cyanine Photosensitizing Dye. M. ISHIHARA, S. FUJISAWA (*Saitama, Japan*). In Vivo 21: 163-174, 2007.

Facts and Fiction of Phytotherapy for Prostate Cancer: A Critical Assessment of Preclinical and Clinical Data. E.C. VON LÖW, F.G.E. PERABO, R. SIENER, S.C. MÜLLER (*Bonn, Germany*). In Vivo 21: 189-204, 2007.

Acridine Orange could be an Innovative Anticancer Agent under Photon Energy. K. KUSUZAKI, H. MURATA, T. MATSUBARA, H. SATONAKA, T. WAKABAYASHI, A. MATSUMINE, A. UCHIDA (*Tsu; Kyoto, Japan*). In Vivo 21: 205-214, 2007.

The Endoplasmic Reticulum: A Target for New Anticancer Drugs. J. BOELENS, S. LUST, F. OFFNER, M.E. BRACKE, B.W. VANHOECKE (*Ghent, Belgium*). In Vivo 21: 215-226, 2007.

Comparison of Multidrug Resistant Efflux Pumps of Cancer and Bacterial Cells with Respect to the Same Inhibitory Agents. L. AMARAL, H. ENGI, M. VIVEIROS, J. MOLNÁR (*Lisboa, Portugal; Szeged, Hungary*). In Vivo 21: 237-244, 2007.

Clinical Pharmacokinetics of Bortezomib. D. LEVÊQUE, M. CHRISTINE M. CARVALHO, F. MALOISEL (*Strasbourg, France*). In Vivo 21: 273-278, 2007.

Selective Toxicity and Type of Cell Death Induced by Various Natural and Synthetic Compounds in Oral Squamous Cell Carcinoma. H. SAKAGAMI, M. KOBAYASHI, C.-H. CHIEN, H. KANEGAE, M. KAWASE (*Saitama; Ehime, Japan*). In Vivo 21: 311-320, 2007.

Molecular Background of Chemoresistance in Pancreatic Cancer. A. ZALATNAI, J. MOLNÁR (*Budapest; Szeged, Hungary*). In Vivo 21: 339-348, 2007.

Pro- and Anti-angiogenesis Effects of Resveratrol. Y. CHEN, S.-H. TSENG (*Taipei; Taoyuan, Taiwan*) 365-370, 2007.

Evidence-based Complementary Oncology. Innovative Approaches to Optimize Standard Therapy Strategies. J. BEUTH, J.M. SCHIERHOLZ (*Cologne; Rosenfeld, Germany*). In Vivo 21: 423-428, 2007.

Advances in Skeletal Muscle Tissue Engineering. J. STERN-STRAETER, F. RIEDEL, G. BRAN, K. HÖRMANN, U.R. GOESSLER (*Mannheim, Germany*). In Vivo 21: 435-444, 2007.

Leukocyte and Endothelial Cell Adhesion Molecules in Inflammation Focusing on Inflammatory Heart Disease. C. GOLIAS, E. TSOUTSI, A. MATZIRIDIS, P. MAKRIDIS, A. BATISTATOU, K. CHARALABOPOULOS (*Ioannina; Edessa, Greece*). In Vivo 21: 757-770, 2007.

Animal Models of Carcinogenesis in the Digestive System. C. TSIGRIS, M. KONSTANTAKAKI, C. XIROMERITIS, N.

NIKITEAS, A. YANNOPOULOS (*Athens, Greece*). *In Vivo* 21: 803-812, 2007.

HuR, an RNA-binding Protein, Involved in the Control of Cellular Differentiation. J. CHERRY, V. KARSCHNER, H. JONES, P.H. PEKALA (*Greenville, NC, USA*). *In Vivo* 20: 17-24, 2006.

The Natural Chemopreventive Compound Indole-3-carbinol: State of the Science. E.G. ROGAN (*Omaha, NE, USA*). *In Vivo* 20: 221-228, 2006.

Critical Roles of Glutamine as Nitrogen Donors in Purine and Pyrimidine Nucleotide Synthesis: Asparaginase Treatment in Childhood Acute Lymphoblastic Leukemia. J.G. CORY, A.H. CORY (*Greenville, NC, USA*). *In Vivo* 20: 587-590, 2006.

Hyperthermia and Immunity. A Brief Overview. G. BARONZIO, A. GRAMAGLIA, G. FIORENTINI (*Monza; Empoli, Italy*). *In Vivo* 20: 689-696, 2006.

Anticancer Drug Delivery with Nanoparticles. M. CONTI, V. TAZZARI, C. BACCINI, G. PERTICI, L.P. SERINO, U. DE GIORGI (*Forlì; Pisa; Empoli, Italy*). *In Vivo* 20: 697-702, 2006.

The PTHrP/PTH.1-R Bioregulation System in Cardiac Hypertrophy: Possible Therapeutic Implications. A. HALAPAS, E. DIAMANTI-KANDARAKIS, D. KREMASTINOS, M. KOUTSILIERIS (*Athens, Greece*). *In Vivo* 20: 837-844, 2006.

New Anticancer Agents: *In Vitro* and *In Vivo* Evaluation. D. ZIPS, H.D. THAMES, M. BAUMANN (*Dresden, Germany; Houston, TX, USA*). *In Vivo* 19: 1-8, 2005.

Radiometallation of Receptor-specific Peptides for Diagnosis and Treatment of Human Cancer. M.F. GIBLIN, B. VEERENDRA, C.J. SMITH (*Columbia, MO, USA*). *In Vivo* 19: 9-30, 2005.

New Anticancer Agents: *In Vitro* and *In Vivo* Evaluation of the Antitumor and Antimetastatic Actions of Various Compounds Isolated from Medicinal Plants. Y. KIMURA (*Ehime, Japan*). *In Vivo* 19: 37-60, 2005.

On the Potential Use of Flavonoids in the Treatment and Prevention of Pancreatic Cancer. A.B. ROGINSKY, M.B. UJIKI, X.-Z. DING, T.E. ADRIAN (*Chicago, IL, USA*). *In Vivo* 19: 61-68, 2005.

Clinical Pharmacokinetics of Imatinib Mesylate. D. LEVÊQUE, F. MALOISEL (*Strasbourg, France*). *In Vivo* 19: 77-84, 2005.

Potential Role of Cell Cycle Synchronizing Agents in Combination Treatment Modalities of Malignant Tumors. A. ZALATNAI (*Budapest, Hungary*). *In Vivo* 19: 85-92, 2005.

Novel Camptothecin Derivatives. K. LEGARZA, L.-X. YANG (*San Francisco, CA, USA*). *In Vivo* 19: 283-292, 2005.

Anticancer Compounds and Sphingolipid Metabolism in the Colon. R.-D. DUAN (*Lund, Sweden*). *In Vivo* 19: 293-300, 2005.

Contribution of Chitosan and its Derivatives to Cancer Chemotherapy. Y. KATO, H. ONISHI, Y. MACHIDA (*Baltimore, MD, USA; Tokyo, Japan*). *In Vivo* 19: 301-310, 2005.

*In Vitro* and *In Vivo* Antiresorptive Effects of Bisphosphonates in Metastatic Bone Disease. I. KANAKIS, O.CH. KOUSIDOU, N.K. KARAMANOS (*Patras, Greece*). *In Vivo* 19: 311-318, 2005.

Cell Cycle and Apoptosis Deregulation in Classical Hodgkin Lymphomas. M. BAI, A. PAPOUDOU-BAI, P. KITSOULIS, N. HORIANOPOULOS, S. KAMINA, N.J. AGNANTIS, P. KANAVAROS (*Ioannina, Greece*). *In Vivo* 19: 439-454, 2005.

Novel Agents in the Treatment of Non-small Cell Lung Cancer: Implications for Neoadjuvant Chemotherapy? M. BERGQVIST, R. HENRIKSSON, D. BRATTSTRÖM (*Uppsala; Umeå, Sweden*) 523-534, 2005.

The Soluble p51 Protein in Cancer Diagnosis, Prevention and Therapy. I. ZUSMAN (*Rehovot, Israel*) 591-598, 2005.

Novel Insights into the Mechanism of Action of Intravesical Immunomodulators. D.N. MITROPOULOS (*Athens, Greece*) 611-622, 2005.

*In Vivo* and *In Vitro* Decondensation of Human Sperm and Assisted Reproduction Technologies. G.S. CAGLAR, M. HAMMADEH, B. ASIMAKOPOULOS, N. NIKOLETTOS, K. DIEDRICH, S. AL-HASSANI (*Lübeck; Homburg/Saar, Germany; Alexandroupolis, Greece*) 623-630, 2005.

Skin Cancer in the Elderly. K.N. SYRIGOS, I. TZANNOU, N. KATIRTZOGLU, E. GEORGIU (*Athens, Greece*) 643-652, 2005.

The Antitumor Activities of Flavonoids. C. KANADASWAMI, L.-T. LEE, P.-P. H LEE, J.-J. HWANG, F.-C. KE, Y.-T. HUANG, M.-T. LEE (*Buffalo, NY; Carrollton, TX, USA; Chia-Yi; Taipei; Kaohsiung, Taiwan*) 895-910, 2005.

Impairments of the 2-5A Synthetase/RNase L Pathway in Chronic Fatigue Syndrome. J. NIJS, K. DE MEIRLEIR (*Brussels; Antwerp, Belgium*) 1013-1022, 2005.